Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

H-2 haplotype-dependent serum IL-12 production in tumor-bearing mice treated with various mycelial extracts.

Yagita A, Maruyama S, Wakasugi S, Sukegawa Y.

In Vivo. 2002 Jan-Feb;16(1):49-54.

PMID:
11980361
2.

Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101.

Sredni B, Tichler T, Shani A, Catane R, Kaufman B, Strassmann G, Albeck M, Kalechman Y.

J Natl Cancer Inst. 1996 Sep 18;88(18):1276-84.

PMID:
8797767
3.

The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.

Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI.

Toxicol Appl Pharmacol. 2007 Jul 15;222(2):152-8. Epub 2007 Apr 20.

PMID:
17555784
5.

[Restoration of immunologic responsiveness by PSK in tumor-bearing animals].

Matsunaga K, Morita I, Oguchi Y, Fujii T, Yoshikumi C, Nomoto K.

Gan To Kagaku Ryoho. 1986 Dec;13(12):3468-75. Japanese.

PMID:
3789758
6.

Suppressive effect of active hexose correlated compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat.

Burikhanov RB, Wakame K, Igarashi Y, Wang S, Matsuzaki S.

Endocr Regul. 2000 Dec;34(4):181-8.

PMID:
11137978
7.

Th1-cytokine induction and anti-tumor effect of 55 kDa protein isolated from Aeginetia indica L., a parasitic plant.

Ohe G, Okamoto M, Oshikawa T, Furuichi S, Nishikawa H, Tano T, Uyama K, Bando T, Yoshida H, Sakai T, Himeno K, Sato M, Ohkubo S.

Cancer Immunol Immunother. 2001 Jul;50(5):251-9.

PMID:
11499808
8.

Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.

Cayeux S, Richter G, Noffz G, Dörken B, Blankenstein T.

J Immunol. 1997 Mar 15;158(6):2834-41.

PMID:
9058819
9.

[Effect of PSK on Th1/Th2 balance in tumor-bearing mice].

Wada T, Iijima H, Sekine F, Kato M, Tsugane M, Oguchi Y, Matsunaga K, Ando T, Nomoto K.

Gan To Kagaku Ryoho. 2003 Oct;30(11):1798-801. Japanese.

PMID:
14619523
10.

Antitumor effect of PSK at a distant site: inductions of interleukin-8-like factor and macrophage chemotactic factor in murine tumor.

Ebina T, Murata K.

Jpn J Cancer Res. 1990 Dec;81(12):1307-13. Erratum in: Jpn J Cancer Res 1991 Feb;82(2):233.

14.

Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus.

Okamoto M, Ohe G, Oshikawa T, Furuichi S, Nishikawa H, Tano T, Ahmed SU, Yoshida H, Moriya Y, Saito M, Sato M.

Cancer Immunol Immunother. 2001 Oct;50(8):408-16.

PMID:
11726135
15.

Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment.

Cowawintaweewat S, Manoromana S, Sriplung H, Khuhaprema T, Tongtawe P, Tapchaisri P, Chaicumpa W.

Asian Pac J Allergy Immunol. 2006 Mar;24(1):33-45.

16.

Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.

Fisher M, Yang LX.

Anticancer Res. 2002 May-Jun;22(3):1737-54. Review.

PMID:
12168863
18.

Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK.

Matsunaga K, Iijima H, Aota M, Oguchi Y, Fujii T, Yoshikumi C, Nomoto K.

J Clin Lab Immunol. 1992 Jan;37(1):21-37.

PMID:
1339233
19.

Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma.

Matsushita K, Kuramitsu Y, Ohiro Y, Obara M, Kobayashi M, Li YQ, Hosokawa M.

Anticancer Drugs. 1998 Apr;9(4):343-50.

PMID:
9635925
20.

Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.

Takeuchi T, Ueki T, Sasaki Y, Kajiwara T, Li B, Moriyama N, Kawabe K.

Cancer Immunol Immunother. 1997 Jan;43(6):375-81.

PMID:
9067410

Supplemental Content

Support Center